LifeSouth Community Blood Centers, Inc.
BiotechLifeSouth Community Blood Centers, Inc. is a biotechnology company with 1 FDA-approved products.
LifeSouth Community Blood Centers, Inc.'s Key Drugs
LifeSouth Community Blood Centers, Inc.'s core commercial portfolio centers on Cordcyte — its most strategically important drugs approved in the last 15 years.
LifeSouth Community Blood Centers, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for LifeSouth Community Blood Centers, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
LifeSouth Community Blood Centers, Inc.'s Therapeutic Areas
Disease areas where LifeSouth Community Blood Centers, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LifeSouth Community Blood Centers, Inc. Pipeline Snapshot
Active clinical trials for LifeSouth Community Blood Centers, Inc. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Cordcyte leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-06-12
- Latest
- 2013-06-12
- Applications
- 1